Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Pedro Salas-AmbrosioDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-0922-4620
Shelby VexlerDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0001-7844-5390
Rajalakshmi P SivasankaranBioPACIFIC Materials Innovation Platform California NanoSystems Institute, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-7781-055X
Niko VlahakisDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Ryan S LaiDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Colin JohnsonDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0003-1092-1172
Sophia I Baas-MaynardDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Daniel S MinDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Haillie LowerDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Abigail G DoyleDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-6641-0833
Yi TangDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Jose A RodriguezDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-0248-4964
Irene A ChenDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0001-6040-7927
Javier Read de AlanizDepartment of Chemistry and Biochemistry and BioPACIFIC Materials Innovation Platform California NanoSystems Institute, University of California, Santa Barbara, California 93106, United States.ORCID 0000-0003-2770-9477
Heather D MaynardDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0003-3692-6289
Funding
Research Training in Cell and Molecular BiologyT32GM145388 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Jorge Torres · 2022 to 2026
$5.2M
Understanding how bacteriophages affect wound ecologies and developing new tools to harness bacteria-phage interactionsDP2GM123457 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI CHEN, IRENE ANN · 2016 to 2016
$2.3M
Phage-inspired engineering and evolutionR35GM148249 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Irene Ann Chen · 2023 to 2026
Antimicrobial resistance is an urgent global health challenge, and compounds that address this issue have attracted significant attention. In particular, bioderived molecules that possess natural antimicrobial properties can be useful to prepare active macromolecules that are degradable. In this work, a 4-(methyl/allyl/benzyl)oxy-6-(H/alkyl)-2-oxy-benzoate-
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Biosourced Functional Hydroxybenzoate- · full record | OpenQuestion